Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan
Authors:
- 1 May 2011
- journal article
- research article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 29 (5) , 890-895
Abstract
Background To investigate the interactive effect of plasma irbesartan concentration and angiotensin II type 1 receptor (AGT1R) gene polymorphisms on blood pressure (BP) response to irbesartan treatment. Methods This study included 1049 Chinese hypertensive patients who were treated with daily oral 150 mg irbesartan for 4 weeks. BP at predose and 28th day of treatment and trough plasma irbesartan concentration (on 28th day of treatment) were measured. Four AGT1R gene polymorphisms (rs2640539, rs1492097, rs388915, rs5186) were genotyped. Multiple linear regression models were used to assess interactive effect of plasma irbesartan concentration and gene polymorphisms on BP response, with adjustment for covariates. Results When stratified by genotypes, patients carrying allele C of single-neucleotide polymorphism (SNP) rs5186 showed positive association between irbesartan concentration and BP response [SBP: β ± SE = 6.1 ± 2.3 with false discovery rate (FDR) P = 0.029; DBP: β ± SE = 2.7 ± 1.0 with FDR P = 0.029], but this was not seen in patients with AA genotype. There was a significant interaction between plasma irbesartan concentration and SNP rs5186 on SBP response (interaction P = 0.0335) and DBP response (interaction P = 0.0190). There also were significant interactions between plasma irbesartan concentration and hap3, hap5 and hap6 (constructed by four genotyped SNPs) on SBP response (FDR P < 0.001), but not on DBP response. Conclusion Our data suggest that AGT1R gene polymorphisms and plasma concentration of irbesartan can act interactively to modulate individual response to antihypertensive therapy using irbesartan.Keywords
This publication has 30 references indexed in Scilit:
- The Relationship Between the Plasma Concentration of Irbesartan and the Antihypertensive Response Is Disclosed by an Angiotensin II Type 1 Receptor Polymorphism: Results From the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) TrialAmerican Journal of Hypertension, 2008
- Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in Rural Chinese patients with essential hypertensionClinical Therapeutics, 2005
- Individual and joint association of α-adrenergic receptor Arg347Cys polymorphism and plasma irbesartan concentration with blood pressure therapeutic response in Chinese hypertensive subjectsClinical Pharmacology & Therapeutics, 2005
- CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese populationEuropean Journal of Clinical Pharmacology, 2005
- Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trialAmerican Journal of Hypertension, 2004
- IrbesartanDrugs, 2004
- Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patientsJournal Of Hypertension, 2001
- Dose-Related Antihypertensive Effects of Irbesartan in Patients With Mild-to-Moderate HypertensionAmerican Journal of Hypertension, 1998
- IrbesartanDrugs, 1997
- Angiotensin Receptors and Their AntagonistsNew England Journal of Medicine, 1996